We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Latest News

News

Clarkston Consulting Accepting Applications for $10K Clarkston Scholars Award in partnership with Pennsylvania Bio

Applications for $10,000 Clarkston Scholars Award now being accepted from eligible undergraduate students focusing in a Life Sciences related field of study.
News

Horizon Discovery Announces £11.3 Million ($18.6 Million) Fundraising

Senior management team and board of directors strengthened with key appointments.
News

Cancer Genetics Appoints Elizabeth A. Czerepak as Chief Financial Officer

Ms. Czerepak will lead the finance, clinical billing operations, human resources, and administrative support functions.
News

VAXIMM Closes a CHF 7.8 Million Financing Round

Company plans to use the proceeds of the financing to progress its lead program VXM01 into and through clinical phase I testing.
News

Whole Genome Sequencing used to Help Inform Cancer Therapy

Physicians and researchers at Mayo Clinic in Arizona and the Translational Genomics Research Institute (TGen) have successfully completed sequencing both a single patients normal and cancer cells - more than 6 billion DNA chemical bases.
News

Everist Genomics Announces External Validation of OncoDefender™-CRC Colorectal Cancer Recurrence Test

New data presented at the ASCO-GI Cancers Symposium demonstrate potential for optimizing clinical management of early stage colon and rectal cancers.
News

SCI Installs First TomoTherapy® Radiation Therapy System in Seattle Metropolitan Area

Introduction of TomoTherapy Treatments at New Ballard, Wash. facility delivers flexibility in treating wide range of Cancers.
News

GE Healthcare Presents Flutemetamol Data for Detection of Amyloid Plaque Linked to Alzheimer's Disease

Five Flutemetamol abstracts to be featured at the 2011 Human Amyloid Imaging Meeting in Miami.
News

Allon Enrolling Patients in Pivotal Davunetide Phase 2/3 Trial

Allon Therapeutics Inc. has announced that it has initiated a pivotal Phase 2/3 clinical trial to evaluate the Company's neuroprotective drug candidate, davunetide, as a potential treatment for progressive supranuclear palsy (PSP), a rapidly-progressing and fatal degenerative brain disease.
News

TauRx Granted European Composition of Matter Patent for Lead Compound in Treatment and Prevention of Neurodegenerative Diseases Including Alzheimer’s Disease

LMTX, poised to enter phase III, in development as a potential neurodegeneration disease modifying agent with a patent life extending to 2027.
Advertisement